Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 1998

View Archived Issues

Potent activity of orally active antiestrogen EM-800 demonstrated in mice

Antiinflammatory/immunomodulating peptide available for licensing from BTG

Herpes simplex virus vaccine reduces HSV-1 corneal disease

MAb F105 is safe for use in AIDS patients

rhGH/rhIGF-1 therapy is tolerable and moderately improves HIV-specific immune function

Beta-sheet breaker peptide potentially effective against amyloidosis in Alzheimer's disease

Company profile: Seattle Genetics

Dipeptidyl peptidase IV inhibitors developed at Tanabe

Micromet awarded grant for genomics-based approach to metastasis

Natural glutamate uptake inhibitors useful for memory disturbances

Neuroprotective agents disclosed by Shionogi

Zeria discovers agents for improving gastrointestinal motility

New PDE V inhibitors in development by Merck KGaA

FDA gives Cerus the go-ahead for testing of RBC pathogen inactivation system

Surfaxin progresses to pivotal testing in patients with ARDS

AxyS, Signal announce drug discovery collaboration

Profile of promising new thiazolidinedione antidiabetic agent from Torii

Italian university researchers investigate peptidomimetic HIV protease inhibitors

Genzyme Transgenics and Lilly to develop novel transgenic protein

ALX-0646 development accelerated

Zeneca's Accolate launched in the U.K.

Fuisz and AHP agreement for CEFORM EA technology

Alexion's C5 inhibitor enters clinic for second autoimmune disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...